金城医药
(300233)
| 流通市值：63.30亿 | | | 总市值：65.37亿 |
| 流通股本：3.72亿 | | | 总股本：3.84亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 721,919,205.16 | 3,373,387,400.67 | 2,515,318,391.16 | 1,758,578,253.52 |
| 营业收入 | 721,919,205.16 | 3,373,387,400.67 | 2,515,318,391.16 | 1,758,578,253.52 |
| 二、营业总成本 | 682,091,200.85 | 3,103,164,108.88 | 2,333,206,417.21 | 1,604,450,464.21 |
| 营业成本 | 475,205,404.72 | 2,019,599,405.01 | 1,505,877,666.08 | 1,044,273,476.63 |
| 税金及附加 | 9,250,592.83 | 39,270,519.84 | 29,272,625.07 | 20,198,433.4 |
| 销售费用 | 74,794,902.94 | 496,387,128.75 | 389,547,908.92 | 278,049,225.02 |
| 管理费用 | 90,172,148.26 | 378,462,118.25 | 284,393,309.03 | 182,345,526.22 |
| 研发费用 | 32,823,976.17 | 170,343,707.78 | 122,556,886.36 | 81,580,181.77 |
| 财务费用 | -155,824.07 | -898,770.75 | 1,558,021.75 | -1,996,378.83 |
| 其中:利息费用 | 3,364,620.19 | 18,478,065.59 | 14,547,591.78 | 10,070,636.55 |
| 其中:利息收入 | 2,394,201.07 | 12,898,144.23 | 10,449,035.67 | 7,475,001.15 |
| 加:公允价值变动收益 | -714.83 | 86,537.6 | -305,092.09 | 464,427.06 |
| 加:投资收益 | 817,894.85 | -1,665,130.72 | -1,524,342.93 | -2,171,637.17 |
| 资产处置收益 | -396,165.76 | 1,454,864.3 | 1,560,628.81 | 1,370,589.59 |
| 资产减值损失(新) | -2,760,402.18 | -32,634,926.91 | -10,161,619.9 | -7,203,414.23 |
| 信用减值损失(新) | 7,015,544.06 | 1,397,494.56 | 4,462,563.61 | 2,623,981.55 |
| 其他收益 | 5,588,626.32 | 28,276,042.26 | 19,122,240.82 | 13,559,537.23 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 50,092,786.77 | 267,138,172.88 | 195,266,352.27 | 162,771,273.34 |
| 加:营业外收入 | 38,759.75 | 3,846,482.49 | 2,175,423.89 | 1,554,331.99 |
| 减:营业外支出 | 331,563.68 | 2,536,632.21 | 500,156.65 | 325,765.45 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 49,799,982.84 | 268,448,023.16 | 196,941,619.51 | 163,999,839.88 |
| 减:所得税费用 | 13,501,079.18 | 60,712,679.03 | 34,840,797.3 | 25,037,355.05 |
| 六、净利润 | 36,298,903.66 | 207,735,344.13 | 162,100,822.21 | 138,962,484.83 |
| 持续经营净利润 | 36,298,903.66 | 207,735,344.13 | 162,100,822.21 | 138,962,484.83 |
| 归属于母公司股东的净利润 | 35,054,760.33 | 196,780,752.11 | 151,053,816.96 | 130,591,570.91 |
| 少数股东损益 | 1,244,143.33 | 10,954,592.02 | 11,047,005.25 | 8,370,913.92 |
| (一)基本每股收益 | 0.09 | 0.52 | 0.4 | 0.34 |
| (二)稀释每股收益 | 0.09 | 0.52 | 0.4 | 0.34 |
| 八、其他综合收益 | - | 23,268,580.25 | - | - |
| 归属于母公司股东的其他综合收益 | - | 23,268,580.25 | - | - |
| 九、综合收益总额 | 36,298,903.66 | 231,003,924.38 | 162,100,822.21 | 138,962,484.83 |
| 归属于母公司股东的综合收益总额 | 35,054,760.33 | 220,049,332.36 | 151,053,816.96 | 130,591,570.91 |
| 归属于少数股东的综合收益总额 | 1,244,143.33 | 10,954,592.02 | 11,047,005.25 | 8,370,913.92 |
| 公告日期 | 2025-04-29 | 2025-03-28 | 2024-10-25 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |